Table 2.

Clinic-pathological features of the “PSM” cohort.

Characteristics		Denosumab	Zoledronic Acid	p value	SMD
n		226	226
Premenopausal State	No	179 (79.2 %)	180 (79.6 %)	1	0.011
	Yes	47 (20.8 %)	46 (20.4 %)
Age (mean ± SD)		62.4 ± 12.1	61.5 ± 11.7	0.41	0.078
PS	0	189 (83.6 %)	187 (82.7 %)	0.9	0.024
	1	37 (16.4 %)	39 (17.3 %)
Histology	Ductal	158 (69.9 %)	150 (66.4 %)	0.71	0.078
	Lobular	51 (22.6 %)	58 (25.7 %)
	Other	17 (7.5 %)	18 (8.0 %)
Ki67 (mean ± SD)		21.5 ± 14.1	21.7 ± 14.9	0.895	0.013
Grading	G1-G2	99 (62.3 %)	122 (66.7 %)	0.462	0.092
	G3	60 (37.7 %)	61 (33.3 %)
Estrogen Receptor (mean ± SD)		85.2 ± 16.1	86.7 ± 14.9	0.313	0.101
Progesterone Receptor (mean ± SD)		45.7 ± 38.2	48.6 ± 36.0	0.438	0.078
Metastatic at Diagnosis	No	135 (59.7 %)	120 (53.1 %)	0.184	0.134
	Yes	91 (40.3 %)	106 (46.9 %)
Adjuvant Chemotherapy	No	148 (65.5 %)	144 (63.7 %)	0.768	0.037
	Yes	78 (34.5 %)	82 (36.3 %)
Adjuvant Endocrine Therapy	No	87 (38.5 %)	91 (40.3 %)	0.773	0.036
	Yes	139 (61.5 %)	135 (59.7 %)
Months of Adjuvant Endocrine Therapy (mean ± SD)		47.6 ± 26.2	41.8 ± 31.2	0.099	0.202
BoneOnly	No	92 (40.7 %)	76 (33.6 %)	0.144	0.147
	Yes	134 (59.3 %)	150 (66.4 %)
CDK4/6 Inhibitor	Abemaciclib	29 (12.8 %)	31 (13.7 %)	0.791	0.064
	Palbociclib	145 (64.2 %)	138 (61.1 %)
	Ribociclib	52 (23.0 %)	57 (25.2 %)
Line of Treatment	First	154 (68.1 %)	159 (70.4 %)	0.683	0.048
	Second	72 (31.9 %)	67 (29.6 %)
Setting	Endocrine Resistant	118 (52.2 %)	111 (49.1 %)	0.572	0.062
	Endocrine Sensitive	108 (47.8 %)	115 (50.9 %)
Endocrine Therapy	Aromatase Inhibitor	134 (59.3 %)	128 (56.6 %)	0.634	0.054
	Fulvestrant	92 (40.7 %)	98 (43.4 %)